|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Wnt signaling and Loxl2 promote aggressive osteosarcoma显示文摘Osteosarcoma(OS)is the most frequent primary malignant bone tumor in urgent need of better therapies.Using genetically modified mouse models(GEMMs),we demonstrate that Wnt signaling promotes c-Fos-induced OS formation via the actions of the collagen-modifying enzyme Loxl2.c-Fos/AP-1 directly regulates the expression of the Wnt ligands Wnt7b and Wnt9a in OS cells through promoter binding,and Wnt7b and Wnt9a in turn promote Loxl2 expression in murine and human OS cells through the transcription factors Zeb1 and Zeb2.Concordantly,inhibition of Wnt ligand secretion by inactivating the Wnt-less(Wls)gene in osteoblasts in c-Fos GEMMs either early or in a therapeutic setting reduces Loxl2 expression and progression of OS.Wls-deficient osteosarcomas proliferate less,are less mineralized and are enriched in fibroblastic cells surrounded by collagen fibers.Importantly,Loxl2 inhibition using either the pan-Lox inhibitor BAPN or a specific inducible shRNA reduces OS cell proliferation in vitro and decreases tumor growth and lung colonization in murine and human orthotopic OS transplantation models.Finally,OS development is delayed in c-Fos GEMMs treated with BAPN or with specific Loxl2 blocking antibodies.Congruently,a strong correlation between c-FOS,LOXL2 and WNT7B/WNT9A expression is observed in human OS samples,and c-FOS/LOXL2 co-expression correlates with OS aggressiveness and decreased patient survival.Therefore,therapeutic targeting of Wnt and/or Loxl2 should be considered to potentiate the inadequate current treatments for pediatric,recurrent,and metastatic OS. | Kazuhiko Matsuoka Latifa Bakiri Lena I.Wolff Markus Linder Amanda Mikels-Vigdal Ana Patiño-García Fernando Lecanda Christine Hartmann Maria Sibilia Erwin F.Wagner | 2020 | Cell Research2020，30，10： | 5 |
| 2 | Fos/AP‐1 proteins in bone and the immune system显示文摘 | Erwin F.Wagner RobertEferl | 2005 | Immunological Reviews2005，，1： | 1 |
| 3 | 制取生物表面活性剂的技术路线显示文摘前言生物表面活性剂是由细菌、酵母和真菌等多种微生物产生的。基本上可分为五种主要类型: 1.糖脂 2.脂肽/脂蛋白 3.脂多糖 4.取代脂肪酸 5.磷脂最近Kosacic等综述了这些细胞外两亲代谢物的产生、性质及各种应用。生物表面活性剂的生物合成常涉及微生物在烃类或其他亲脂性底物上的生长。生物表面活性剂在烃代谢中的生理作用与亲脂底物和微生物细胞间的起始作用机理有关。除烃外,油脂、甘油或碳水化合物等非烃类也可作为微生物合成生物活性剂的碳底物。视所用的微生物种类,合成过程可以是生长相关或非生长相关的。 | F.Wagner 胡征宇 | 1989 | 日用化学工业译丛1989，，4： | 1 |
| 4 | Ultrahigh temporal contrast performance of the PHELIX petawatt facility显示文摘We report on the temporal contrast performance of the PHELIX facility in view of the requirements imposed by solidtarget interaction experiments. The requirement analysis for the nanosecond and picosecond temporal contrast is derived from empirical data and simple theoretical modeling, while the realization shows that using an ultrafast optical parametric amplifier and plasma mirrors enables meeting this specification. | V.Bagnoud F.Wagner | 2016 | High Power Laser Science and Engineering2016，4，4： | 0 |
| 5 | Accelerating ions with high-energy short laser pulses from submicrometer thick targets显示文摘Using the example of the PHELIX high-energy short pulse laser we discuss the technical preconditions to investigate ion acceleration with submicrometer thick targets. We show how the temporal contrast of this system was improved to prevent pre-ionization of such targets on the nanosecond timescale. Furthermore the influence of typical fluctuations or uncertainties of the on-target intensity on ion acceleration experiments is discussed. We report how these uncertainties were reduced by improving the assessment and control of the on-shot intensity and by optimizing the positioning of the target into the focal plane. Finally we report on experimental results showing maximum proton energies in excess of 85 MeV for ion acceleration via the target normal sheath acceleration mechanism using target thicknesses on the order of one micrometer. | F.Wagner C.Brabetz O.Deppert M.Roth T.Stohlker An.Tauschwitz A.Tebartz B.Zielbauer V.Bagnoud | 2016 | High Power Laser Science and Engineering2016，4，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员